Garner Resume - Accellient Partners

C. Edwin Garner, PhD
Affiliate Scientist
Summary. Drug discovery and development expert with extensive experience in small molecules. Areas of
experience and expertise include:
•
•
•
•
•
•
•
•
Drug Development through Phase 1
Regulatory Strategies and IND Filing
Project Planning and Execution
CRO Management
Pharmacokinetics
Biotransformation
Clinical and Preclinical PK/PD
Transporters
Professional Experience
Accellient Partners
Affiliate Scientist: 2014-present
Oso Corredor Scientific Consulting.
Principal: 2013-Present
Lovelace Respiratory Research Institute
Director Drug Metabolism & Pharmacokinetics: 2011-2013
Institute for Drug Discovery.
Director Drug Metabolism & Pharmacokinetics: 2009-2010
AstraZeneca.
Principal Scientist, DMPK: 2006-2010
Research Triangle Institute
Sr Research Pharmacokineticist:2003-2006
Schering Plough Research Institute,
Associate Principal Scientist, Drug Metabolism and Pharmacokinetics: 2001 to 2003
DuPont-Merck Pharmaceuticals
Research Scientist, Drug Metabolism and Pharmacokinetics: 1999 to 2001
Education/Certification
1991; BS, Chemistry, Barton College
1999; PhD, Toxicology, North Carolina State University
Drug Development Experience
•
•
•
•
•
Drug discovery and drug development – Anti-infectives (TB, MRSA), oncology, respiratory, rheumatology,
cardiovascular.
Pharmacokinetic and pharmacodynamic modeling; preclinical and clinical pharmacokinetic applications in
WinNonlin and Berkeley Madonna software
Physiologically Based Pharmacokinetic Modeling (PBPK)
Pharmacokinetic/pharmacodynamic study design and interpretation
Interspecies scaling of pharmacokinetics to select clinical doses
Confidential
Page 1
2014
•
•
•
•
Transporter and metabolism studies using Caco-2, isolated perfused rat kidney, isolated perfused rat liver,
Ussing chamber, and in situ perfused intestine models.
In vitro and in vivo biotransformation, metabolite ID and characterization
P450 methodologies and drug-drug interaction studies (in vivo and in vitro)
Acute and Chronic animal models (rodents, dog and primates) for absorption, first-pass effects and
formulation development
Selected Publications
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
G. S. Basarab, P J. Hill, C. Edwin Garner, K. Hull, O. Green, B. A. Sherer, P. B. Dangel, J. I. Manchester, S. Bist,
S. Hauck, F. Zhou, M. Uria-Nickelsen, R. Illingworth, R. Alm, M. Rooney, and A. E. Eakin. Optimization of
Pyrrolamide Topoisomerase II Inhibitors Towards Identification of the Antibacterial Clinical Candidate AZD5099.
J. Med. Chem. (Submitted).
C. E. Garner and J. Yu. (2014). Species and Sex –dependent Toxicokinetics of 1-Bromopropane: the Role of
Hepatic Cytochrome P450 Oxidation and Glutathione (GSH) Xenobiotica (Eprint: January 17, 2014).
Medvetz, D., Sun, Y., Li, C., Priolo, C., Yu, J., Shamu, C., McDonald, J., Garner, C.E., Flood, D., Henske, E.
High-throughput chemical screening identifies Chelerythrine Chloride as a selective inducer of death in TSC2-null
cells via the induction of ROS-mediated necroptosis". Nature Chemical Biology (Submitted)
C. Edwin Garner, Christopher J. Wegerski, Joseph Lucak, Melanie Doyle-Eisele, Benjamin Moeller, Jacob D.
McDonald, J. Michael Sanders, and Suramya Waidyanatha. Disposition and Metabolism of 2',2'Dithiobisbenzanilide (DTBBA) in Harlan Sprague Dawley Rats and B6C3F1/N Mice after Oral Gavage and
Intravenous Administration, and Dermal Application Toxicology Applied Pharmacology (Submitted).
C. Emond; J. Raymer; C.E. Garner; D. Studebaker, J; L. S. Birnbaum (2010). A physiologically-based
pharmacokinetic (PBPK) model for developmental exposure to PBDE-47 in rat. Toxicol. Applied Pharmacol,
242(3):290-8.
Goteti K, Garner CE, Utley L, Ashwell S, Schwartz , GK, Gönen, M, Zabludoff S & Brassil PJ. (2010).
Pharmacokinetic/pharmacodynamic models of pre-clinical tumor growth following combination therapy with
anticancer agents. Clin. Cancer Res. 66(2):245-54
Goteti, K., Garner, C E, Mahmood, I. (2010) Prediction of human drug clearance from two species: A comparison
of several allometric methods. J. Pharmaceutical Sci. 99(3):1601-13.
Goteti K, Brassil PJ, Good SS, Garner CE (2008). Estimation of human drug clearance using multiexponential
techniques. J Clin Pharmacol 48(10):1226.
Garner CE, Ho PW, Ho JW, Leung KC, Chu AC, Kwok KH, Kung MH, Burka LT, Ramsden DB, Ho SL (2008).
Estrogenic Phenol and Catechol Metabolites of PCBs Modulate Catechol-O-Methyltransferase Expression Via the
Estrogen Receptor: Potential Contribution to Cancer Risk. Curr Drug Metab. 9(4):304.
Garner CE, Solon E, Lai CM, Lin J, Luo G, Jones K, Duan J, Decicco CP, Maduskuie T, Mercer SE, Gan LS, Qian
M, Prakash S, Shen HS, Lee FW (2008). Role of P-glycoprotein and the intestine in the excretion of DPC 333 in
rodents. Drug Metab Dispos.36(6):1102.
Qian M, Bai SA, Brogdon B, Wu JT, Liu RQ, Covington MB, Vaddi K, Newton RC, Fossler MJ, Garner CE, Deng
Y, Maduskuie T, Trzaskos J, Duan JJ, Decicco CP, Christ DD (2007). Pharmacokinetics and pharmacodynamics
of DPC 333, a potent and selective inhibitor of tumor necrosis factor alpha-converting enzyme in rodents, dogs,
chimpanzees, and humans. Drug Metab Dispos. 35(10):1916.
Luo G, Garner CE, Xiong H, Hu H, Richards LE, Brouwer KL, Duan J, Decicco CP, Maduskuie T, Shen H, Lee
FW, Gan LS (2007). Effect of DPC, a human tumor necrosis factor alpha-converting enzyme inhibitor, on the
disposition of methotrexate: a transporter-based drug-drug interaction case study. Drug Metab Dispos. 35(6):835.
Garner CE, Sloan C, Sumner SC, Burgess J, Davis J, Etheridge A, Parham A, Ghanayem BI. (2007) CYP2E1catalyzed oxidation contributes to the sperm toxicity of 1-bromopropane in mice. Biol Reprod., 76, 496.
C.E. Garner, S.C. J. Sumner, J.G. Davis, J. P. Burgess, Y. Yueh, J. Demeter, Q. Zhan, J. Valentine, A. R.
Jeffcoat, L. T. Burka, and J.M. Mathews. (2006). Metabolism and Disposition of 1-Bromopropane in Rats and Mice
Following Inhalation or Intravenous Administration Toxicol. Applied Pharmacol 215(1):23.
C.E. Garner, J. Demeter, and H. B. Matthews (2006). The Effect of Chlorine Substitution on the Disposition of
Polychlorinated Biphenyls Following Dermal Administration. Toxicol. Applied Pharmacol 216(1):157.
Raymer, J; Studabaker, W; Michael, L; Garner, C E. (2006). Development of a PBPK Model for 2,2',4,4'Tetrabromodiphenyl Ether in Rats and its Extrapolation to Humans for Measurement of In Utero Exposures.
Epidemiology. 17(6): 94.
Professional Affiliations
•
•
American Association for Pharmaceutical Scientists
International Society for the Study of Xenobiotics
Confidential
Page 2
2014

Download Report